The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy

Data ReadoutDeramiocelPositive

AI Analysis

Summary

Capricor Therapeutics announced that The Lancet published HOPE-3 data for Deramiocel in Duchenne Muscular Dystrophy. This represents a significant clinical milestone for the company's cell-based therapeutic program.

Clinical Trial Data

Outcome Details

HOPE-3 data published in The Lancet

Importance:6/10

Sentiment:

0.60

cell therapyexosome therapyrare diseasemuscular dystrophyclinical data publication

Related Companies

$CAPR

Read the original article

Published by Drugs.com Clinical Trial Results on July 29, 2026 5:07 AM

Read Original